| Transaction Date | Recipient | Shares | Type | Price | Value |
|---|---|---|---|---|---|
| 21st May 2020 | Omar Khwaja | 3,500 | Open or private sale | $12.96 | $45,360.00 |
| 3rd April 2020 | Robert W. Hesslein | 3,091 | Open or private sale | $8.51 | $26,304.41 |
| 10th February 2020 | Omar Khwaja | 30,000 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Andre Turenne | 81,250 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Robert W. Hesslein | 27,500 | Grant/award etc. | $0.00 | |
| 10th February 2020 | Allison Dorval | 27,500 | Grant/award etc. | $0.00 | |
| 21st January 2020 | Matthew P. Ottmer | 3,724 | Open or private sale | $13.36 | $49,752.64 |
| 21st January 2020 | Andre Turenne | 10,705 | Open or private sale | $13.36 | $143,018.80 |
| 21st January 2020 | Allison Dorval | 3,128 | Open or private sale | $13.36 | $41,790.08 |
| 20th May 2019 | Omar Khwaja | 30,000 | Grant/award etc. | $0.00 |
Voyager Therapeutics
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Ticker: VYGR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1640266
Employees: 185
Exchange: NASDAQ
Auditor Opinion:
You must Login to see Language Changes
Disclosure Language changes
You must Login to see analysis
Red Flags
There were no Red Flags found
Fundamentals
Cash at Carrying Value: $144 M (0%)
Marketable Securities, Current: $85 M (-56%)
Assets, Current: $247 M (-19%)
Property, Plant and Equipment, Net: $20 M (12%)
Assets: $297 M (-16%)
Accounts Payable, Current: $2 M (-49%)
Accrued Liabilities, Current: $18 M (0%)
Liabilities, Current: $68 M (-11%)
Other Liabilities, Noncurrent: $30 M (0%)
Liabilities: $221 M (-13%)
Common Stock, Value, Issued: $37 Th (0%)
Common Stock, Shares, Issued: $37 M (0%)
Retained Earnings (Accumulated Deficit): $346 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $145 Th (39%)
Stockholders' Equity (Parent): $77 M (0%)
Liabilities and Equity: $297 M (-16%)
Revenue: $29 M (-38%)
Research and Development: $29 M (-52%)
General and Administrative Expenses: $8 M (-55%)
Operating Income/Loss: $9 M (-73%)
Other Income, net: $300 Th (-36%)
EPS (basic): $0.23 (-74%)
EPS (diluted): $0.23 (-74%)
News
Threat to democracy? Tech CEOs in hot seat over liability shield
27th October 2020
Airbnb looks to list on Nasdaq
27th October 2020
Sonia Syngal is trying to build The Gap into a bolder brand
27th October 2020